As the WSJ blog did, this story’s interview quotes provided important perspectives:
This was a well done story about a very well done study with important practice and policy implications.
The story stated: “Colonoscopy costs vary widely but typically exceed $1,000. While Medicare rules say the government won’t pay for too-frequent colonoscopies, only 2 percent of the study claims were denied for repeat exams in people without symptoms.”
We’ll give the story the benefit of the doubt for deftly summarizing the story in this way: “The older you are, the more likely you are to die from other causes before cancer becomes deadly, which means the screening procedure’s risks may outweigh its benefits in many aged patients, the study authors said.”
Mixed bag, but we’ll give the story the benefit of the doubt because, in comparison with some stories we reviewed at least this story mentioned what some of the harms were, stating: “The exam is generally pretty safe, but does have risks that occur more often with older patients, including complications from sedation, accidental perforation of the colon and bleeding.”
We wish the story had given some sense of how often these problems occur.
Adequate job explaining the study.
The theme of this story was the opposite of disease-mongering.
The story turned to an American Cancer Society source and to a Medicare spokesperson for comment.
The story did include the perspective that “while colonoscopies may be overused in the elderly, the exams and other colon cancer screening methods are underused among some groups, including the uninsured, blacks and Hispanics.”
Besides not offering any comparison with other screening methods, the story never mentioned what other screening methods are and it would have taken only a line to do so.
The availability of colonoscopies is not in question.
The relative novelty of this study was clear from the story.
It’s clear that the story did not rely solely on a news release.
Systematic, Criteria-Driven
Questions to ask about new Alzheimer’s drug research by @KatKStone incl:
-does study focus on patient outcomes or surrogate markers?
-does study rely on selective subgroups? (yield more favourable outcomes)
-who were the patients? https://www.healthnewsreview.org/2017/08/6-questions-to-ask-when-writing-and-reading-about-new-alzheimers-research/#.YRw5xNVXths.twitter @HealthNewsRevu
Monday at #ADA2021, an infectious disease epidemiologist, a journalist, and a researcher shared perspectives on communication of risk in the era of COVID-19: http://ow.ly/ROfR30rMeE7 @AstleyCM @garyschwitzer @berthahidalgo @ADA_DiabetesPro
Shoutouts to @susan_bewley @drkevinknopf @MichaelBaum11 in this call for more than fawning coverage from press releases for these kinds of stories.
Also, linked history inside goes back 5 years just on Grail apparently trying to become Holy Grail. https://twitter.com/garyschwitzer/status/1408849696416841731
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like